Johnson & Johnson (JNJ) Gross Margin (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Gross Margin came in at 66.31% in Q1 2026, down 8.0% year-on-year from 72.08% in Q1 2025, and down 1.85% quarter-over-quarter from 67.56% in Q4 2025.
Johnson & Johnson (JNJ) Gross Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Gross Margin across 18 years of filings, most recently posting 66.31% for Q1 2026.
- Gross Margin for Q1 2026 came in at 66.31%, down 8.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 67.82% (down 48.0% YoY), and the FY2025 annual result was 67.88%, down 119.0% from the prior year.
- Gross Margin came in at 66.31% for Q1 2026 at Johnson & Johnson, down from 67.56% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 69.97% in Q3 2023 to a low of 66.31% in Q1 2026.
- The 5-year median for Gross Margin is 69.01% (2024), against an average of 68.6%.
- Across the five-year window, Gross Margin soared 155 bps in 2024 and slumped 315 bps in 2025, its largest moves.
- Johnson & Johnson's Gross Margin stood at 69.13% in 2022, then declined by 1 bps to 68.23% in 2023, then gained by 0 bps to 68.35% in 2024, then slipped by 1 bps to 67.56% in 2025, then dropped by 2 bps to 66.31% in 2026.
- The last three Gross Margin figures came in at 66.31% (Q1 2026), 67.56% (Q4 2025), and 69.56% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 70.22% |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 66.31% |
| Dec 28, 2025 | 67.56% |
| Sep 28, 2025 | 69.56% |
| Jun 29, 2025 | 67.87% |
| Mar 30, 2025 | 66.40% |
| Dec 29, 2024 | 68.35% |
| Sep 29, 2024 | 69.01% |
| Jun 30, 2024 | 69.40% |
| Mar 31, 2024 | 69.55% |
| Dec 31, 2023 | 68.23% |
| Oct 1, 2023 | 69.06% |
| Jul 2, 2023 | 69.97% |
| Apr 2, 2023 | 68.00% |
| Jan 1, 2023 | 69.49% |
| Oct 2, 2022 | 69.13% |
| Jul 3, 2022 | 68.73% |
| Apr 3, 2022 | 69.67% |
| Oct 3, 2021 | 68.93% |
| Jul 4, 2021 | 67.45% |
| Apr 4, 2021 | 68.36% |